Alkermes (ALKS) Reports Early ADHD Drug Results. Can a Larger Trial Show it Works?

insidermonkey.com · 2026-09-26

Alkermes plc (NASDAQ:ALKS) reported on September 21 that adults receiving the investigational oral drug ALKS 7290 showed improved symptoms of attention-deficit hyperactivity disorder (ADHD).

TickrTrends take: Alkermes reported early results for an ADHD drug candidate, with the critical question being whether a larger trial will validate efficacy at scale. Given TickrTrends' current overvalued assessment, investors should monitor whether this development provides genuine pipeline value or whether market enthusiasm has already priced in optimistic outcomes. The Healthcare sector context suggests that clinical execution risk and trial success rates warrant careful scrutiny before any valuation re-rating could be justified.

Read the full story at insidermonkey.com →